Large cytoplasmic ribonucleoprotein particles that have an eight-fold symmetry with a central pore and petal-like structure giving the appearance of an octagonal dome. (The Dictionary of Cell Biology, Lackie and Dow, 2nd ed.)
Complexes of RNA-binding proteins with ribonucleic acids (RNA).
Highly conserved nuclear RNA-protein complexes that function in RNA processing in the nucleus, including pre-mRNA splicing and pre-mRNA 3'-end processing in the nucleoplasm, and pre-rRNA processing in the nucleolus (see RIBONUCLEOPROTEINS, SMALL NUCLEOLAR).
A family of ribonucleoproteins that were originally found as proteins bound to nascent RNA transcripts in the form of ribonucleoprotein particles. Although considered ribonucleoproteins they are primarily classified by their protein component. They are involved in a variety of processes such as packaging of RNA and RNA TRANSPORT within the nucleus. A subset of heterogeneous-nuclear ribonucleoproteins are involved in additional functions such as nucleocytoplasmic transport (ACTIVE TRANSPORT, CELL NUCLEUS) of RNA and mRNA stability in the CYTOPLASM.
Proteins conjugated with nucleic acids.
A nuclear RNA-protein complex that plays a role in RNA processing. In the nucleoplasm, the U1 snRNP along with other small nuclear ribonucleoproteins (U2, U4-U6, and U5) assemble into SPLICEOSOMES that remove introns from pre-mRNA by splicing. The U1 snRNA forms base pairs with conserved sequence motifs at the 5'-splice site and recognizes both the 5'- and 3'-splice sites and may have a fundamental role in aligning the two sites for the splicing reaction.
Short chains of RNA (100-300 nucleotides long) that are abundant in the nucleus and usually complexed with proteins in snRNPs (RIBONUCLEOPROTEINS, SMALL NUCLEAR). Many function in the processing of messenger RNA precursors. Others, the snoRNAs (RNA, SMALL NUCLEOLAR), are involved with the processing of ribosomal RNA precursors.
A group of closely related heterogeneous-nuclear ribonucleoproteins of approximately 41-43 kDa in size found in the cell nucleus. Members of this class have been implicated in a variety of processes including splicing, polyadenylation, and nuclear retention of RNA.
A nuclear RNA-protein complex that plays a role in RNA processing. In the nucleoplasm, the U2 snRNP along with other small nuclear ribonucleoproteins (U1, U4-U6, and U5) assemble into SPLICEOSOMES that remove introns from pre-mRNA by splicing. The U2 snRNA forms base pairs with conserved sequence motifs at the branch point, which associates with a heat- and RNAase-sensitive factor in an early step of splicing.
A class of closely related heterogeneous-nuclear ribonucleoproteins of approximately 34-40 kDa in size. Although they are generally found in the nucleoplasm, they also shuttle between the nucleus and the cytoplasm. Members of this class have been found to have a role in mRNA transport, telomere biogenesis and RNA SPLICING.
Nuclear nonribosomal RNA larger than about 1000 nucleotides, the mass of which is rapidly synthesized and degraded within the cell nucleus. Some heterogeneous nuclear RNA may be a precursor to mRNA. However, the great bulk of total hnRNA hybridizes with nuclear DNA rather than with mRNA.
Proteins that bind to RNA molecules. Included here are RIBONUCLEOPROTEINS and other proteins whose function is to bind specifically to RNA.
The ultimate exclusion of nonsense sequences or intervening sequences (introns) before the final RNA transcript is sent to the cytoplasm.
A polynucleotide consisting essentially of chains with a repeating backbone of phosphate and ribose units to which nitrogenous bases are attached. RNA is unique among biological macromolecules in that it can encode genetic information, serve as an abundant structural component of cells, and also possesses catalytic activity. (Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed)
Relating to the size of solids.
A heterogeneous-nuclear ribonucleoprotein found in the CELL NUCLEUS and the CYTOPLASM. Heterogeneous-nuclear ribonucleoprotein K has been implicated in the regulation of gene expression at nearly all levels: GENETIC TRANSCRIPTION; mRNA processing (RNA PROCESSING, POST-TRANSCRIPTIONAL), mRNA transport, mRNA stability, and translation (TRANSLATION, GENETIC). The hnRNP protein has a strong affinity for polypyrimidine-rich RNA and for single-stranded polypyrimidine-rich DNA. Multiple hnRNP K protein isoforms exist due to alternative splicing and display different nucleic-acid-binding properties.
RNA transcripts of the DNA that are in some unfinished stage of post-transcriptional processing (RNA PROCESSING, POST-TRANSCRIPTIONAL) required for function. RNA precursors may undergo several steps of RNA SPLICING during which the phosphodiester bonds at exon-intron boundaries are cleaved and the introns are excised. Consequently a new bond is formed between the ends of the exons. Resulting mature RNAs can then be used; for example, mature mRNA (RNA, MESSENGER) is used as a template for protein production.
Organelles in which the splicing and excision reactions that remove introns from precursor messenger RNA molecules occur. One component of a spliceosome is five small nuclear RNA molecules (U1, U2, U4, U5, U6) that, working in conjunction with proteins, help to fold pieces of RNA into the right shapes and later splice them into the message.
A nuclear RNA-protein complex that plays a role in RNA processing. In the nucleoplasm, the U4-U6 snRNP along with the U5 snRNP preassemble into a single 25S particle that binds to the U1 and U2 snRNPs and the substrate to form mature SPLICEOSOMES. There is also evidence for the existence of individual U4 or U6 snRNPs in addition to their organization as a U4-U6 snRNP.
The protein components that constitute the common core of small nuclear ribonucleoprotein particles. These proteins are commonly referred as Sm nuclear antigens due to their antigenic nature.
Nucleolar RNA-protein complexes that function in pre-ribosomal RNA processing.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for VIRUS CULTIVATION and antitumor drug screening assays.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Small RNAs found in the cytoplasm usually complexed with proteins in scRNPs (RIBONUCLEOPROTEINS, SMALL CYTOPLASMIC).
Within a eukaryotic cell, a membrane-limited body which contains chromosomes and one or more nucleoli (CELL NUCLEOLUS). The nuclear membrane consists of a double unit-type membrane which is perforated by a number of pores; the outermost membrane is continuous with the ENDOPLASMIC RETICULUM. A cell may contain more than one nucleus. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)
The spatial arrangement of the atoms of a nucleic acid or polynucleotide that results in its characteristic 3-dimensional shape.
A nuclear RNA-protein complex that plays a role in RNA processing. In the nucleoplasm, the U5 snRNP along with U4-U6 snRNP preassemble into a single 25S particle that binds to the U1 and U2 snRNPs and the substrate to form SPLICEOSOMES.
A heterogeneous-nuclear ribonucleoprotein found associated with the NUCLEAR MATRIX.
Complexes of scRNA (RNA, SMALL CYTOPLASMIC) and protein found in the cytoplasm. An example is SIGNAL RECOGNITION PARTICLE.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.

Recombinant major vault protein is targeted to neuritic tips of PC12 cells. (1/147)

The major vault protein (MVP) is the predominant constituent of ubiquitous, evolutionarily conserved large cytoplasmic ribonucleoprotein particles of unknown function. Vaults are multimeric protein complexes with several copies of an untranslated RNA. Double labeling employing laser-assisted confocal microscopy and indirect immunofluorescence demonstrates partial colocalization of vaults with cytoskeletal elements in Chinese hamster ovary (CHO) and nerve growth factor (NGF)-treated neuronlike PC12 cells. Transfection of CHO and PC12 cells with a cDNA encoding the rat major vault protein containing a vesicular stomatitis virus glycoprotein epitope tag demonstrates that the recombinant protein is sorted into vault particles and targeted like endogenous MVPs. In neuritic extensions of differentiated PC12 cells, there is an almost complete overlap of the distribution of microtubules and vaults. A pronounced colocalization of vaults with filamentous actin can be seen in the tips of neurites. Moreover, in NGF-treated PC12 cells the location of vaults partially coincides with vesicular markers. Within the terminal tips of neurites vaults are located near secretory organelles. Our observations suggest that the vault particles are transported along cytoskeletal-based cellular tracks.  (+info)

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. (2/147)

Therapeutic resistance is a major obstacle in the treatment of acute myeloid leukemia (AML). Such resistance has been associated with rapid drug efflux mediated by the multidrug resistance gene 1 (MDR1; encoding P-glycoprotein) and more recently with expression of other novel proteins conferring multidrug resistance such as MRP1 (multidrug resistance-associated protein 1) and LRP (lung resistance protein). To determine the frequency and clinical significance of MDR1, MRP1, and LRP in younger AML patients, we developed multiparameter flow cytometric assays to quantify expression of these proteins in pretreatment leukemic blasts from 352 newly diagnosed AML patients (median age, 44 years) registered to a single clinical trial (SWOG 8600). Protein expression was further correlated with functional efflux by leukemic blasts [assessed using two substrates: Di(OC)(2) and Rhodamine 123] and with the ability of MDR-reversing agents to inhibit efflux in vitro. MDR1/P-glycoprotein expression, which was highly correlated with cyclosporine-inhibited efflux, was noted in only 35% of these younger AML patients, distinctly lower than the frequency of 71% we previously reported in AML in the elderly (Blood 89:3323, 1997). Interestingly, MDR1 expression and functional drug efflux increased with patient age, from a frequency of only 17% in patients less than 35 years old to 39% in patients aged 50 years (P =.010). In contrast, MRP1 was expressed in only 10% of cases and decreased with patient age (P =. 024). LRP was detected in 43% of cases and increased significantly with increasing white blood cell counts (P =.0015). LRP was also marginally associated with favorable cytogenetics (P =.012) and French-American-British (FAB) AML FAB subtypes (P =.013), being particularly frequent in M4/M5 cases. Only MDR1/P-glycoprotein expression and cyclosporine-inhibited efflux were significantly associated with complete remission (CR) rate (P(MDR1) =.012; P(efflux) =.039) and resistant disease (RD; P(MDR1) =.0007; P(efflux) =.0092). No such correlations were observed for MRP1 (P(CR) =.93; P(RD) =.55) or LRP (P(CR) =.50; P(RD) =.53). None of these parameters were associated with overall or relapse-free survival. Unexpectedly, a distinct and nonoverlapping phenotype was detected in 18% of these cases: cyclosporine-resistant efflux not associated with MDR1, MRP1, or LRP expression, implying the existence of other as yet undefined efflux mechanisms in AML. In summary, MDR1 is less frequent in younger AML patients, which may in part explain their better response to therapy. Neither MRP1 nor LRP are significant predictors of outcome in this patient group. Thus, inclusion of MDR1-modulators alone may benefit younger AML patients with MDR1(+) disease.  (+info)

Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas. (3/147)

We have established new human sarcoma lines and examined their sensitivity to common antitumor drugs and expression of putative multidrug resistance (MDR) proteins. Eighty-two sarcoma samples were transplanted in nude mice. Fourteen of these sarcomas were established as tumor cell lines. We determined a chemosensitivity profile to antitumor drugs (MDR drugs = doxorubicin, mitoxantrone, and vincristine; non-MDR drugs = cisplatin, ifosfamide, and bleomycin) for each tumor line in vivo. Response to chemotherapy with doxorubicin and ifosfamide was observed in 30-50% of these tumor lines. Our results obtained with xenotransplants are similar to the results documented in clinical trials in which doxorubicin and ifosfamide are effective in 30-50% of the patients. Furthermore, we examined expression of MDR-relevant markers like P-glycoprotein, MDR-associated protein, lung resistance protein, and mdr1 mRNA in these xenotransplants. A relationship between mdr1 mRNA expression and response to doxorubicin was demonstrated in >90% of our tumor lines. In six sarcomas with mdr1 mRNA expression, five were resistant against doxorubicin and cross-resistant against several other drugs, whereas from eight sarcomas, which lacked detectable mdr1 mRNA, seven were sensitive to doxorubicin and other drugs. We found lung resistance protein or MDR-associated protein expressed in three resistant and mdr1 mRNA-positive sarcomas. These results demonstrate that mdr1 mRNA expression is a putative marker for drug resistance in our sarcoma lines. We conclude, therefore, that inherent P-glycoprotein expression might be also responsible for drug resistance occurring in treatment of patients with sarcomas. The established tumor lines are useful for additional investigations on mechanisms of drug resistance in sarcomas and as models for preclinical screening of new antitumor drugs.  (+info)

The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. (4/147)

Mammalian vaults are ribonucleoprotein (RNP) complexes, composed of a small ribonucleic acid and three proteins of 100, 193, and 240 kD in size. The 100-kD major vault protein (MVP) accounts for >70% of the particle mass. We have identified the 193-kD vault protein by its interaction with the MVP in a yeast two-hybrid screen and confirmed its identity by peptide sequence analysis. Analysis of the protein sequence revealed a region of approximately 350 amino acids that shares 28% identity with the catalytic domain of poly(ADP-ribose) polymerase (PARP). PARP is a nuclear protein that catalyzes the formation of ADP-ribose polymers in response to DNA damage. The catalytic domain of p193 was expressed and purified from bacterial extracts. Like PARP, this domain is capable of catalyzing a poly(ADP-ribosyl)ation reaction; thus, the 193-kD protein is a new PARP. Purified vaults also contain the poly(ADP-ribosyl)ation activity, indicating that the assembled particle retains enzymatic activity. Furthermore, we show that one substrate for this vault-associated PARP activity is the MVP. Immunofluorescence and biochemical data reveal that p193 protein is not entirely associated with the vault particle, suggesting that it may interact with other protein(s). A portion of p193 is nuclear and localizes to the mitotic spindle.  (+info)

Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. (5/147)

Expression of the lung resistance protein (LRP) is associated with resistance to various anticancer drugs including melphalan and, therefore, may affect the clinical outcome in multiple myeloma (MM). To determine the clinical significance of LRP, we have compared LRP expression in bone marrow plasma cells with clinical parameters including response to chemotherapy and survival of previously untreated patients with MM (n = 72). LRP expression immunocytochemically assessed by means of the LRP-56 monoclonal antibody was positive (> or =10% staining plasma cells) in 44 (61%) samples. There was no correlation between LRP expression and age, sex, type of the paraprotein, serum creatinine, stage, beta2-microglobulin, serum lactate dehydrogenase, or C-reactive protein. However, LRP expression was more frequently observed in patients with a p53 deletion than in those without such a deletion (P = 0.01). The overall response rate for all of the patients evaluable for response to induction chemotherapy (n = 58) was 67%. The response rate was 87% for patients without LRP expression but only 54% for patients with LRP expression (P = 0.01). Kaplan-Meier analysis revealed that patients with LRP expression had a shorter overall survival (median, 33 months) than those without LRP expression (median not reached; P = 0.04). These data show that LRP expression is an important marker for clinical drug resistance and predicts a poor outcome in MM.  (+info)

Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. (6/147)

BACKGROUND: Lung resistance-related protein (LRP), the major vault protein in humans, is sometimes overexpressed in multidrug-resistant cells. Because cells transfected with the LRP gene did not express the multidrug-resistant phenotype, we investigated whether LRP is involved in multidrug resistance. METHODS: SW-620 cells, a human colon carcinoma cell line, alone or transfected with an expression vector carrying a LRP-specific ribozyme or with an empty vector, were treated with sodium butyrate to induce differentiation. Expression of P-glycoprotein, multidrug resistance protein, and LRP in the cells was examined by northern and western blotting, and the efflux of doxorubicin in the cells or isolated nuclei was examined by fluorescence microscopy. RESULTS: A 2-week treatment with sodium butyrate induced LRP and conferred resistance to doxorubicin, vincristine, etoposide, gramicidin D, and paclitaxel (Taxol) in SW-620 cells. Insertion of either of two LRP-specific ribozymes into SW-620 cells inhibited these activities. Levels of drugs accumulating in the cells were not decreased by sodium butyrate, suggesting that the adenosine triphosphate-binding cassette transporter is not involved in sodium butyrate-induced multidrug resistance. Doxorubicin was mainly located in the nuclei of untreated cells and in the cytoplasm of sodium butyrate-treated cells. Isolated nuclei from untreated cells or sodium butyrate-treated cells incubated with anti-LRP polyclonal antibodies contained more doxorubicin than the nuclei of sodium butyrate-treated cells alone. Efflux of doxorubicin was greater from the nuclei of sodium butyrate-treated cells than the nuclei of untreated cells or of sodium butyrate-treated cells transfected with a LRP-specific ribozyme and was inhibited by an anti-LRP polyclonal antibody. CONCLUSIONS: LRP is involved in resistance to doxorubicin, vincristine, etoposide, paclitaxel, and gramicidin D and has an important role in the transport of doxorubicin from the nucleus to the cytoplasm.  (+info)

Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. (7/147)

Intrinsic and/or acquired resistance to chemotherapy is the major obstacle to overcome in the treatment of patients with ovarian carcinoma. The aim of the present study was to investigate the prognostic value of drug resistance-associated proteins P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1), canalicular multispecific organic anion transporter (c-MOAT/MRP2), and lung resistance protein (LRP) in ovarian carcinoma. Expression of P-gp, MRP1, MRP2, and LRP was determined by immunohistochemistry of frozen tissue sections of 115 ovarian carcinoma patients and related to clinicopathological factors, response to chemotherapy, and progression-free survival. P-gp expression was observed in 20 of 115 (17%), MRP1 in 51 (44%), MRP2 in 19 (16%), and LRP in 85 (74%) tumors. Expression of MRP1 was related to MRP2 (P<0.0001) and P-gp (P<0.001) expression, whereas LRP expression was more frequently observed in patients with early stage (P<0.01), lower grade (P<0.05), and smaller residual tumor (P<0.05). Early stage (P<0.001), smaller residual tumor (P<0.001), and lower differentiation grade (P<0.05) were related to longer (progression-free) survival. P-gp, MRP1, MRP2, and LRP expression were neither related to response to first-line chemotherapy in 59 evaluable patients nor to progression-free survival in all patients. On multivariate analysis, only stage and residual tumor were independent prognostic factors for survival. In conclusion, in ovarian carcinoma, MRP1 expression is associated with MRP2 and P-gp expression, whereas LRP expression is associated with favorable clinicopathological characteristics. Assessment of P-gp, MRP1, MRP2, or LRP does not allow prediction of response to chemotherapy or survival in ovarian carcinoma.  (+info)

Vaults and telomerase share a common subunit, TEP1. (8/147)

Vaults are large cytoplasmic ribonucleoprotein complexes of undetermined function. Mammalian vaults have two high molecular mass proteins of 193 and 240 kDa. We have identified a partial cDNA encoding the 240-kDa vault protein and determined it is identical to the mammalian telomerase-associated component, TEP1. TEP1 is the mammalian homolog of the Tetrahymena p80 telomerase protein and has been shown to interact specifically with mammalian telomerase RNA and the catalytic protein subunit hTERT. We show that while TEP1 is a component of the vault particle, vaults have no detectable telomerase activity. Using a yeast three-hybrid assay we demonstrate that several of the human vRNAs interact in a sequence-specific manner with TEP1. The presence of 16 WD40 repeats in the carboxyl terminus of the TEP1 protein is a convenient number for this protein to serve a structural or organizing role in the vault, a particle with eight-fold symmetry. The sharing of the TEP1 protein between vaults and telomerase suggests that TEP1 may play a common role in some aspect of ribonucleoprotein structure, function, or assembly.  (+info)

Vault ribonucleoprotein particles (vault RNPs or vaults) are large, complex, and evolutionarily conserved cellular structures found in the cytoplasm of eukaryotic cells. They were first identified in 1986 due to their vault-like morphology observed under an electron microscope. Vault RNPs have a hollow barrel-shaped structure with a height of approximately 67 nm and a diameter of about 42 nm, composed primarily of multiple copies of three proteins (major vault protein, MVP; telomerase-associated protein 1, TEP1; and vault poly(ADP-ribose) polymerase, VPARP) and small untranslated RNAs called vault RNAs (vRNAs).

The exact function of vault RNPs remains to be fully elucidated, but they have been implicated in various cellular processes such as:

1. Intracellular transport and trafficking: Vault RNPs may play a role in the transport of molecules across membranes, including drug efflux pumps and the export of specific mRNAs from the nucleus to the cytoplasm.
2. Cell signaling and regulation: Vault RNPs have been suggested to participate in cellular responses to stress, inflammation, and hypoxia by modulating various signaling pathways, including those involving MAPK, PI3K/AKT, and NF-κB.
3. Drug resistance: The overexpression of vault components has been associated with multidrug resistance in cancer cells, possibly due to their involvement in drug efflux pumps or other detoxification mechanisms.
4. Viral defense: Vault RNPs may contribute to the cell's antiviral response by interacting with viral particles and inhibiting their replication.
5. Telomere maintenance: TEP1, a component of vault RNPs, has been found to associate with telomerase, suggesting a potential role in telomere maintenance and chromosome stability.

Despite these proposed functions, further research is needed to fully understand the molecular mechanisms and physiological relevance of vault RNPs in various cellular processes.

Ribonucleoproteins (RNPs) are complexes composed of ribonucleic acid (RNA) and proteins. They play crucial roles in various cellular processes, including gene expression, RNA processing, transport, stability, and degradation. Different types of RNPs exist, such as ribosomes, spliceosomes, and signal recognition particles, each having specific functions in the cell.

Ribosomes are large RNP complexes responsible for protein synthesis, where messenger RNA (mRNA) is translated into proteins. They consist of two subunits: a smaller subunit containing ribosomal RNA (rRNA) and proteins that recognize the start codon on mRNA, and a larger subunit with rRNA and proteins that facilitate peptide bond formation during translation.

Spliceosomes are dynamic RNP complexes involved in pre-messenger RNA (pre-mRNA) splicing, where introns (non-coding sequences) are removed, and exons (coding sequences) are joined together to form mature mRNA. Spliceosomes consist of five small nuclear ribonucleoproteins (snRNPs), each containing a specific small nuclear RNA (snRNA) and several proteins, as well as numerous additional proteins.

Other RNP complexes include signal recognition particles (SRPs), which are responsible for targeting secretory and membrane proteins to the endoplasmic reticulum during translation, and telomerase, an enzyme that maintains the length of telomeres (the protective ends of chromosomes) by adding repetitive DNA sequences using its built-in RNA component.

In summary, ribonucleoproteins are essential complexes in the cell that participate in various aspects of RNA metabolism and protein synthesis.

Small nuclear ribonucleoproteins (snRNPs) are a type of ribonucleoprotein (RNP) found within the nucleus of eukaryotic cells. They are composed of small nuclear RNA (snRNA) molecules and associated proteins, which are involved in various aspects of RNA processing, particularly in the modification and splicing of messenger RNA (mRNA).

The snRNPs play a crucial role in the formation of spliceosomes, large ribonucleoprotein complexes that remove introns (non-coding sequences) from pre-mRNA and join exons (coding sequences) together to form mature mRNA. Each snRNP contains a specific snRNA molecule, such as U1, U2, U4, U5, or U6, which recognizes and binds to specific sequences within the pre-mRNA during splicing. The associated proteins help stabilize the snRNP structure and facilitate its interactions with other components of the spliceosome.

In addition to their role in splicing, some snRNPs are also involved in other cellular processes, such as transcription regulation, RNA export, and DNA damage response. Dysregulation or mutations in snRNP components have been implicated in various human diseases, including cancer, neurological disorders, and autoimmune diseases.

Heterogeneous Nuclear Ribonucleoproteins (hnRNPs) are a type of nuclear protein complex associated with nascent RNA transcripts in the nucleus of eukaryotic cells. They play crucial roles in various aspects of RNA metabolism, including processing, transport, stability, and translation.

The term "heterogeneous" refers to the diverse range of proteins that make up these complexes, while "nuclear" indicates their location within the nucleus. The hnRNPs are composed of a core protein component and associated RNA molecules, primarily heterogeneous nuclear RNAs (hnRNAs) or pre-messenger RNAs (pre-mRNAs).

There are over 20 different hnRNP proteins identified so far, each with distinct functions and structures. Some of the well-known hnRNPs include hnRNP A1, hnRNP C, and hnRNP U. These proteins contain several domains that facilitate RNA binding, protein-protein interactions, and post-translational modifications.

The primary function of hnRNPs is to regulate gene expression at the post-transcriptional level by interacting with RNA molecules. They participate in splicing, 3' end processing, export, localization, stability, and translation of mRNAs. Dysregulation of hnRNP function has been implicated in various human diseases, including neurological disorders and cancer.

Nucleoproteins are complexes formed by the association of proteins with nucleic acids (DNA or RNA). These complexes play crucial roles in various biological processes, such as packaging and protecting genetic material, regulating gene expression, and replication and repair of DNA. In these complexes, proteins interact with nucleic acids through electrostatic, hydrogen bonding, and other non-covalent interactions, leading to the formation of stable structures that help maintain the integrity and function of the genetic material. Some well-known examples of nucleoproteins include histones, which are involved in DNA packaging in eukaryotic cells, and reverse transcriptase, an enzyme found in retroviruses that transcribes RNA into DNA.

A ribonucleoprotein, U1 small nuclear (U1 snRNP) is a type of small nuclear ribonucleoprotein (snRNP) particle that is found within the nucleus of eukaryotic cells. These complexes are essential for various aspects of RNA processing, particularly in the form of spliceosomes, which are responsible for removing introns from pre-messenger RNA (pre-mRNA) during the process of gene expression.

The U1 snRNP is composed of a small nuclear RNA (snRNA) molecule called U1 snRNA, several proteins, and occasionally other non-coding RNAs. The U1 snRNA contains conserved sequences that recognize and bind to specific sequences in the pre-mRNA, forming base pairs with complementary regions within the intron. This interaction is crucial for the accurate identification and removal of introns during splicing.

In addition to its role in splicing, U1 snRNP has been implicated in other cellular processes such as transcription regulation, RNA decay, and DNA damage response. Dysregulation or mutations in U1 snRNP components have been associated with various human diseases, including cancer and neurological disorders.

Small nuclear RNA (snRNA) are a type of RNA molecules that are typically around 100-300 nucleotides in length. They are found within the nucleus of eukaryotic cells and are components of small nuclear ribonucleoproteins (snRNPs), which play important roles in various aspects of RNA processing, including splicing of pre-messenger RNA (pre-mRNA) and regulation of transcription.

There are several classes of snRNAs, each with a distinct function. The most well-studied class is the spliceosomal snRNAs, which include U1, U2, U4, U5, and U6 snRNAs. These snRNAs form complexes with proteins to form small nuclear ribonucleoprotein particles (snRNPs) that recognize specific sequences in pre-mRNA and catalyze the removal of introns during splicing.

Other classes of snRNAs include signal recognition particle (SRP) RNA, which is involved in targeting proteins to the endoplasmic reticulum, and Ro60 RNA, which is associated with autoimmune diseases such as systemic lupus erythematosus.

Overall, small nuclear RNAs are essential components of the cellular machinery that regulates gene expression and protein synthesis in eukaryotic cells.

Heterogeneous Nuclear Ribonucleoproteins (hnRNPs) are a group of nuclear proteins that are involved in the processing and metabolism of RNA. The 'Group C' hnRNPs refer to a specific subclass of these proteins, which include hnRNP C1 and hnRNP C2. These proteins are highly similar in their amino acid sequences and have molecular weights of approximately 34-36 kDa. They play important roles in various aspects of RNA metabolism, including pre-mRNA splicing, mRNA stability, and translation. Mutations in hnRNP C proteins have been associated with certain neurological disorders, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

A ribonucleoprotein, U2 small nuclear (U2 snRNP) is a type of spliceosomal small nuclear ribonucleoprotein (snRNP) complex that plays a crucial role in the pre-messenger RNA (pre-mRNA) splicing process during gene expression in eukaryotic cells.

Pre-mRNA splicing is the removal of non-coding sequences, called introns, from the pre-mRNA molecule and the joining together of the remaining coding sequences, or exons, to form a continuous mRNA sequence that can be translated into protein. U2 snRNPs are essential components of the spliceosome, the large ribonucleoprotein complex responsible for pre-mRNA splicing.

The U2 snRNP is composed of several proteins and a small nuclear RNA (snRNA) molecule called U2 small nuclear RNA (U2 snRNA). The U2 snRNA binds to specific sequences within the pre-mRNA, forming part of the intron's branch site, which helps define the boundaries of the exons and introns. This interaction facilitates the recognition and assembly of other spliceosomal components, ultimately leading to the precise excision of introns and ligation of exons in the mature mRNA molecule.

In summary, U2 snRNP is a ribonucleoprotein complex involved in pre-mRNA splicing, where it plays a critical role in recognizing and processing intron-exon boundaries during gene expression in eukaryotic cells.

Heterogeneous Nuclear Ribonucleoproteins (hnRNPs) are a group of nuclear proteins that are involved in the processing and metabolism of messenger RNA (mRNA). They were named "heterogeneous" because they were initially found to be associated with a heterogeneous population of RNA molecules. The hnRNPs are divided into several subfamilies, A and B being two of them.

The hnRNP A-B group is composed of proteins that share structural similarities and have overlapping functions in the regulation of mRNA metabolism. These proteins play a role in various aspects of RNA processing, including splicing, 3' end processing, transport, stability, and translation.

The hnRNP A-B group includes several members, such as hnRNPA1, hnRNPA2/B1, and hnRNPC. These proteins contain RNA recognition motifs (RRMs) that allow them to bind to specific sequences in the RNA molecules. They can also interact with other proteins and form complexes that regulate mRNA function.

Mutations in genes encoding hnRNP A-B group members have been associated with several human diseases, including neurodegenerative disorders, myopathies, and cancer. Therefore, understanding the structure and function of these proteins is essential for elucidating their role in disease pathogenesis and developing potential therapeutic strategies.

Heterogeneous Nuclear RNA (hnRNA) is a type of RNA molecule found in the nucleus of eukaryotic cells during the early stages of gene expression. The term "heterogeneous" refers to the diverse range of sizes and structures that these RNAs exhibit, which can vary from several hundred to tens of thousands of nucleotides in length.

HnRNA is transcribed from DNA templates by the enzyme RNA polymerase II and includes both introns (non-coding sequences) and exons (coding sequences) that will eventually be spliced together to form mature mRNA molecules. HnRNA also contains additional sequences, such as 5' cap structures and 3' poly(A) tails, which are added during post-transcriptional processing.

Because hnRNA is a precursor to mature mRNA, it is often used as a marker for transcriptionally active genes. However, not all hnRNA molecules are ultimately processed into mRNA; some may be degraded or converted into other types of RNA, such as microRNAs or long non-coding RNAs.

Overall, hnRNA plays a critical role in the regulation and expression of genes in eukaryotic cells.

RNA-binding proteins (RBPs) are a class of proteins that selectively interact with RNA molecules to form ribonucleoprotein complexes. These proteins play crucial roles in the post-transcriptional regulation of gene expression, including pre-mRNA processing, mRNA stability, transport, localization, and translation. RBPs recognize specific RNA sequences or structures through their modular RNA-binding domains, which can be highly degenerate and allow for the recognition of a wide range of RNA targets. The interaction between RBPs and RNA is often dynamic and can be regulated by various post-translational modifications of the proteins or by environmental stimuli, allowing for fine-tuning of gene expression in response to changing cellular needs. Dysregulation of RBP function has been implicated in various human diseases, including neurological disorders and cancer.

RNA splicing is a post-transcriptional modification process in which the non-coding sequences (introns) are removed and the coding sequences (exons) are joined together in a messenger RNA (mRNA) molecule. This results in a continuous mRNA sequence that can be translated into a single protein. Alternative splicing, where different combinations of exons are included or excluded, allows for the creation of multiple proteins from a single gene.

RNA (Ribonucleic Acid) is a single-stranded, linear polymer of ribonucleotides. It is a nucleic acid present in the cells of all living organisms and some viruses. RNAs play crucial roles in various biological processes such as protein synthesis, gene regulation, and cellular signaling. There are several types of RNA including messenger RNA (mRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), small nuclear RNA (snRNA), microRNA (miRNA), and long non-coding RNA (lncRNA). These RNAs differ in their structure, function, and location within the cell.

In the context of medical and health sciences, particle size generally refers to the diameter or dimension of particles, which can be in the form of solid particles, droplets, or aerosols. These particles may include airborne pollutants, pharmaceutical drugs, or medical devices such as nanoparticles used in drug delivery systems.

Particle size is an important factor to consider in various medical applications because it can affect the behavior and interactions of particles with biological systems. For example, smaller particle sizes can lead to greater absorption and distribution throughout the body, while larger particle sizes may be filtered out by the body's natural defense mechanisms. Therefore, understanding particle size and its implications is crucial for optimizing the safety and efficacy of medical treatments and interventions.

Heterogeneous Nuclear Ribonucleoprotein K (hnRNP K) is a member of the family of heterogeneous nuclear ribonucleoproteins (hnRNPs), which are proteins that bind to RNA molecules in the nucleus of eukaryotic cells. These proteins play important roles in various aspects of RNA metabolism, including processing, transport, and stability.

Specifically, hnRNP K is a multifunctional protein that has been shown to participate in several cellular processes, such as transcription, splicing, mRNA stabilization, and translation. It can bind to both DNA and RNA molecules, and its binding affinity is influenced by various post-translational modifications, including phosphorylation, methylation, and acetylation.

hnRNP K has been implicated in the development and progression of several human diseases, including cancer, neurodegenerative disorders, and viral infections. Its expression levels and subcellular localization are often altered in these conditions, making it a potential target for therapeutic intervention.

RNA precursors, also known as primary transcripts or pre-messenger RNAs (pre-mRNAs), refer to the initial RNA molecules that are synthesized during the transcription process in which DNA is copied into RNA. These precursor molecules still contain non-coding sequences and introns, which need to be removed through a process called splicing, before they can become mature and functional RNAs such as messenger RNAs (mRNAs), ribosomal RNAs (rRNAs), or transfer RNAs (tRNAs).

Pre-mRNAs undergo several processing steps, including 5' capping, 3' polyadenylation, and splicing, to generate mature mRNA molecules that can be translated into proteins. The accurate and efficient production of RNA precursors and their subsequent processing are crucial for gene expression and regulation in cells.

A spliceosome is a complex of ribonucleoprotein (RNP) particles found in the nucleus of eukaryotic cells that removes introns (non-coding sequences) from precursor messenger RNA (pre-mRNA) and joins exons (coding sequences) together to form mature mRNA. This process is called splicing, which is an essential step in gene expression and protein synthesis. Spliceosomes are composed of five small nuclear ribonucleoprotein particles (snRNPs), known as U1, U2, U4/U6, and U5 snRNPs, and numerous proteins. The assembly of spliceosomes and the splicing reaction are highly regulated and can be influenced by various factors, including cis-acting elements in pre-mRNA and trans-acting factors such as serine/arginine-rich (SR) proteins.

A ribonucleoprotein, U4-U6 small nuclear (snRNP) is a type of small nuclear ribonucleoprotein particle that plays a crucial role in the splicing of pre-messenger RNA (pre-mRNA) in the nucleus of eukaryotic cells. Specifically, U4-U6 snRNP is part of the spliceosome complex, which catalyzes the removal of introns (non-coding sequences) from pre-mRNA during the process of gene expression.

The U4-U6 snRNP is composed of several proteins and three small nuclear RNAs (snRNAs): U4, U6, and U6atac. These snRNAs are highly conserved across different species and are essential for the stability and function of the U4-U6 snRNP complex. The U4 and U6 snRNAs form a specific base-pairing interaction that is critical for the assembly and activity of the spliceosome.

During splicing, the U4-U6 snRNP interacts with other snRNPs (U1, U2, and U5) to form a large ribonucleoprotein complex called the spliceosome. The U4-U6 snRNP then undergoes a series of conformational changes that ultimately lead to the formation of the active site for splicing. This process involves the displacement of U4 snRNA from U6 snRNA, allowing U6 snRNA to base-pair with the intron and form the catalytic core of the spliceosome.

Defects in U4-U6 snRNP biogenesis or function have been implicated in various human diseases, including cancer, neurological disorders, and autoimmune diseases.

SnRNP (small nuclear ribonucleoprotein) core proteins are a group of proteins that are associated with small nuclear RNAs (snRNAs) to form small nuclear ribonucleoprotein particles. These particles play crucial roles in various aspects of RNA processing, such as splicing, 3' end formation, and degradation.

The snRNP core proteins include seven Sm proteins (B, D1, D2, D3, E, F, and G) that form a heptameric ring-like structure called the Sm core, which binds to a conserved sequence motif in the snRNAs called the Sm site. In addition to the Sm proteins, there are also other core proteins such as Sm like (L) proteins and various other protein factors that associate with specific snRNP particles.

Together, these snRNP core proteins help to stabilize the snRNA, facilitate its assembly into functional ribonucleoprotein complexes, and participate in the recognition and processing of target RNAs during post-transcriptional regulation.

Small nucleolar ribonucleoproteins (snoRNPs) are a type of ribonucleoprotein complex found in the nucleus of eukaryotic cells. They play a crucial role in the post-transcriptional modification of ribosomal RNA (rRNA) and small nuclear RNA (snRNA). Specifically, snoRNPs are responsible for guiding the addition of methyl groups to specific nucleotides in rRNA and snRNA, a process known as 2'-O-methylation.

Small nucleolar ribonucleoproteins are composed of two main components: a small nucleolar RNA (snoRNA) and several proteins. The snoRNA molecule contains a conserved sequence that base-pairs with the target rRNA or snRNA, forming a structure that positions the methyl group donor enzyme, methyltransferase, in close proximity to the nucleotide to be modified.

Small nucleolar ribonucleoproteins are classified into two main categories based on their snoRNA components: box C/D snoRNPs and box H/ACA snoRNPs. Box C/D snoRNPs guide 2'-O-methylation, while box H/ACA snoRNPs are responsible for pseudouridination, another type of RNA modification.

Overall, small nucleolar ribonucleoproteins play a critical role in maintaining the stability and functionality of rRNAs and snRNAs, which are essential components of the translation and splicing machinery in eukaryotic cells.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

HeLa cells are a type of immortalized cell line used in scientific research. They are derived from a cancer that developed in the cervical tissue of Henrietta Lacks, an African-American woman, in 1951. After her death, cells taken from her tumor were found to be capable of continuous division and growth in a laboratory setting, making them an invaluable resource for medical research.

HeLa cells have been used in a wide range of scientific studies, including research on cancer, viruses, genetics, and drug development. They were the first human cell line to be successfully cloned and are able to grow rapidly in culture, doubling their population every 20-24 hours. This has made them an essential tool for many areas of biomedical research.

It is important to note that while HeLa cells have been instrumental in numerous scientific breakthroughs, the story of their origin raises ethical questions about informed consent and the use of human tissue in research.

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

"Small cytoplasmic RNAs" (scRNAs) are a heterogeneous group of non-coding RNA molecules that are typically 100-300 nucleotides in length and are located within the cytoplasm of cells. They play various roles in post-transcriptional regulation of gene expression, including serving as components of ribonucleoprotein complexes involved in mRNA splicing, stability, and translation.

Some specific types of scRNAs include small nuclear RNAs (snRNAs), which are involved in spliceosomal complexes that remove introns from pre-mRNA; small nucleolar RNAs (snoRNAs), which guide chemical modifications of other RNA molecules, such as ribosomal RNAs (rRNAs); and microRNAs (miRNAs), which bind to target mRNAs and inhibit their translation or promote their degradation.

It's worth noting that the term "small cytoplasmic RNA" is a broad category, and individual scRNAs can have distinct functions and characteristics.

The cell nucleus is a membrane-bound organelle found in the eukaryotic cells (cells with a true nucleus). It contains most of the cell's genetic material, organized as DNA molecules in complex with proteins, RNA molecules, and histones to form chromosomes.

The primary function of the cell nucleus is to regulate and control the activities of the cell, including growth, metabolism, protein synthesis, and reproduction. It also plays a crucial role in the process of mitosis (cell division) by separating and protecting the genetic material during this process. The nuclear membrane, or nuclear envelope, surrounding the nucleus is composed of two lipid bilayers with numerous pores that allow for the selective transport of molecules between the nucleoplasm (nucleus interior) and the cytoplasm (cell exterior).

The cell nucleus is a vital structure in eukaryotic cells, and its dysfunction can lead to various diseases, including cancer and genetic disorders.

Nucleic acid conformation refers to the three-dimensional structure that nucleic acids (DNA and RNA) adopt as a result of the bonding patterns between the atoms within the molecule. The primary structure of nucleic acids is determined by the sequence of nucleotides, while the conformation is influenced by factors such as the sugar-phosphate backbone, base stacking, and hydrogen bonding.

Two common conformations of DNA are the B-form and the A-form. The B-form is a right-handed helix with a diameter of about 20 Å and a pitch of 34 Å, while the A-form has a smaller diameter (about 18 Å) and a shorter pitch (about 25 Å). RNA typically adopts an A-form conformation.

The conformation of nucleic acids can have significant implications for their function, as it can affect their ability to interact with other molecules such as proteins or drugs. Understanding the conformational properties of nucleic acids is therefore an important area of research in molecular biology and medicine.

A ribonucleoprotein, U5 small nuclear (snRNP), is a type of spliceosomal small nuclear ribonucleoprotein (snRNP) particle that plays a crucial role in the process of pre-messenger RNA (pre-mRNA) splicing. Pre-mRNA splicing is the removal of non-coding sequences, called introns, from the pre-mRNA molecule and the joining together of the remaining coding sequences, or exons, to form a mature mRNA molecule that can be translated into protein.

The U5 snRNP particle consists of a small uridine-rich RNA (U5 snRNA) molecule and several associated proteins. The U5 snRNA contains highly conserved sequences that are important for its recognition by the other components of the spliceosome, which is the large ribonucleoprotein complex responsible for pre-mRNA splicing.

During the splicing process, the U5 snRNP particle interacts with other snRNP particles (U1, U2, and U4/U6) to form a functional spliceosome that catalyzes the splicing reaction. The U5 snRNA base-pairs with the intron sequences at the 5' and 3' splice sites, helping to position the exons for splicing. After the splicing reaction is complete, the U5 snRNP particle is released from the spliceosome and can be recycled for further rounds of splicing.

Defects in the components of the U5 snRNP particle have been implicated in several human diseases, including certain forms of cancer and neurological disorders.

Heterogeneous Nuclear Ribonucleoprotein U (hnRNP U) is a member of the family of heterogeneous nuclear ribonucleoproteins (hnRNPs). These proteins are involved in various aspects of RNA metabolism, including processing, transport, and stability. Specifically, hnRNP U, also known as scaffold attachment factor B (SAF-B), is a protein that binds to scaffold/matrix attachment regions (S/MARs) of the genome and helps to tether RNA to the nuclear matrix during transcription and processing. It has also been implicated in DNA repair processes.

Small cytoplasmic ribonucleoproteins (scRNPs) are a type of ribonucleoprotein complex found in the cytoplasm of eukaryotic cells. They are composed of several proteins and a small, non-coding RNA molecule known as small nuclear RNA (snRNA). Specifically, scRNPs contain a unique class of snRNAs called U1, U2, U4, U5, and U6 small nuclear RNAs.

These complexes play crucial roles in various aspects of RNA metabolism, particularly in the processing of messenger RNA (mRNA) during gene expression. They are involved in splicing, a process that removes non-coding sequences called introns from pre-mRNA and joins together the remaining coding sequences, or exons, to form mature mRNAs.

The protein components of scRNPs help stabilize the snRNA molecules, facilitate their assembly into functional complexes, and participate in the recognition and binding of specific RNA sequences during splicing. Dysregulation of scRNP function or composition can lead to various human diseases, including cancer and neurological disorders.

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

Vault Ribonucleoprotein Particles. Large cytoplasmic ribonucleoprotein particles that due to structure give appearance of an ...
Vault website (UCLA). - Web archive (28 Feb. 2009) Vault+Ribonucleoprotein+Particles at the U.S. National Library of Medicine ... Kedersha NL, Heuser JE, Chugani DC, Rome LH (January 1991). "Vaults. III. Vault ribonucleoprotein particles open into flower- ... Vaults are large ribonucleoprotein particles. About 3 times the size of a ribosome and weighing approximately 13 MDa, they are ... "The Telomerase/vault-associated protein TEP1 is required for vault RNA stability and its association with the vault particle". ...
VAULT RIBONUCLEOPROTEIN PARTICLES. PARTICULAS DE RIBONUCLEOPROTEINAS ABOVEDADAS. PATIENT SELF-DETERMINATION ACT. PATIENT SELF- ...
The human major vault protein (MVP) has been implicated in the development of drug resistance in cancer cells. Over expression ... Vault Ribonucleoprotein Particles / genetics* Actions. * Search in PubMed * Search in MeSH * Add to Search ... Major vault protein plays important roles in viral infection. Wang W, Xiong L, Wang P, Wang F, Ma Q. Wang W, et al. IUBMB Life ... Major vault protein (MVP) gene polymorphisms and drug resistance in mesial temporal lobe epilepsy with hippocampal sclerosis ...
A vault ribonucleoprotein particle exhibiting 39-fold dihedral symmetry.. Kato K; Tanaka H; Sumizawa T; Yoshimura M; Yamashita ... 2. The formation of vault-tubes: a dynamic interaction between vaults and vault PARP.. van Zon A; Mossink MH; Schoester M; ... Characterization of MVP and VPARP assembly into vault ribonucleoprotein complexes.. Zheng CL; Sumizawa T; Che XF; Tsuyama S; ... 4. Vaults and the major vault protein: novel roles in signal pathway regulation and immunity.. Berger W; Steiner E; Grusch M; ...
Vaults, cytoplasmic ubiquitous ribonucleoprotein particles, can be engineered to encapsulate heterologous proteins while ... Vault nanocapsule packaged CCL21 (CCL21-vaults). Lung Lewis carcinoma 3LL cells. Efficient CCL21 delivery to sustain antitumor ... Intratumoral administration of vault packaged CCL21 (CCL21-vaults) enhanced leukocytes infiltrates, inhibited lung tumor growth ... CCL21 vaults. Lung 3LL tumor cells. Enhanced leukocyte infiltration, inhibition of lung tumor growth and reduction of the ...
Vault Ribonucleoprotein Particles Vault RNP Particles use Vault Ribonucleoprotein Particles vav Proto-Oncogene Protein use ...
Ribonucleoprotein Particles, Vault Vault RNP Particles Registry Number. 0. Previous Indexing. Ribonucleoproteins (1986-1998). ... Vault Ribonucleoprotein Particles Preferred Term Term UI T060245. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1999). ... Ribonucleoprotein Particles, Vault Term UI T060244. Date04/10/1998. LexicalTag NON. ThesaurusID NLM (1999). ... Vault Ribonucleoprotein Particles Preferred Concept UI. M0030039. Registry Number. 0. Scope Note. Large cytoplasmic ...
Ribonucleoprotein Particles, Vault Vault RNP Particles Registry Number. 0. Previous Indexing. Ribonucleoproteins (1986-1998). ... Vault Ribonucleoprotein Particles Preferred Term Term UI T060245. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1999). ... Ribonucleoprotein Particles, Vault Term UI T060244. Date04/10/1998. LexicalTag NON. ThesaurusID NLM (1999). ... Vault Ribonucleoprotein Particles Preferred Concept UI. M0030039. Registry Number. 0. Scope Note. Large cytoplasmic ...
Vault Ribonucleoprotein Particles Vault RNP Particles use Vault Ribonucleoprotein Particles vav Proto-Oncogene Protein use ...
VAULT RIBONUCLEOPROTEIN PARTICLES. PARTICULAS DE RIBONUCLEOPROTEINAS ABOVEDADAS. PATIENT SELF-DETERMINATION ACT. PATIENT SELF- ...
VAULT RIBONUCLEOPROTEIN PARTICLES. PARTICULAS DE RIBONUCLEOPROTEINAS ABOVEDADAS. PARTÍCULAS DE RIBONUCLEOPROTEÍNAS EM FORMA DE ...
VAULT RIBONUCLEOPROTEIN PARTICLES. PARTICULAS DE RIBONUCLEOPROTEINAS ABOVEDADAS. PATIENT SELF-DETERMINATION ACT. PATIENT SELF- ...
VAULT RIBONUCLEOPROTEIN PARTICLES. PARTICULAS DE RIBONUCLEOPROTEINAS ABOVEDADAS. PATIENT SELF-DETERMINATION ACT. PATIENT SELF- ...
VAULT RIBONUCLEOPROTEIN PARTICLES. PARTICULAS DE RIBONUCLEOPROTEINAS ABOVEDADAS. PATIENT SELF-DETERMINATION ACT. PATIENT SELF- ...
VAULT RIBONUCLEOPROTEIN PARTICLES. PARTICULAS DE RIBONUCLEOPROTEINAS ABOVEDADAS. PATIENT SELF-DETERMINATION ACT. PATIENT SELF- ...
VAULT RIBONUCLEOPROTEIN PARTICLES. PARTICULAS DE RIBONUCLEOPROTEINAS ABOVEDADAS. PATIENT SELF-DETERMINATION ACT. PATIENT SELF- ...
VAULT RIBONUCLEOPROTEIN PARTICLES. PARTICULAS DE RIBONUCLEOPROTEINAS ABOVEDADAS. PATIENT SELF-DETERMINATION ACT. PATIENT SELF- ...
VAULT RIBONUCLEOPROTEIN PARTICLES. PARTÍCULAS DE RIBONUCLEOPROTEÍNAS EM FORMA DE ABÓBADA. PATIENT SELF-DETERMINATION ACT. ...
VAULT RIBONUCLEOPROTEIN PARTICLES. PARTICULAS DE RIBONUCLEOPROTEINAS ABOVEDADAS. PATIENT SELF-DETERMINATION ACT. PATIENT SELF- ...
VAULT RIBONUCLEOPROTEIN PARTICLES. PARTICULAS DE RIBONUCLEOPROTEINAS ABOVEDADAS. PATIENT SELF-DETERMINATION ACT. PATIENT SELF- ...
VAULT RIBONUCLEOPROTEIN PARTICLES. PARTICULAS DE RIBONUCLEOPROTEINAS ABOVEDADAS. PATIENT SELF-DETERMINATION ACT. PATIENT SELF- ...
VAULT RIBONUCLEOPROTEIN PARTICLES. PARTICULAS DE RIBONUCLEOPROTEINAS ABOVEDADAS. PATIENT SELF-DETERMINATION ACT. PATIENT SELF- ...
Vault Ribonucleoprotein Particles 28% Powered by Pure, Scopus & Elsevier Fingerprint Engine™ All content on this site: ...
The major vault protein (MVP) is the main constituent of the vault ribonucleoprotein particle. Although the role in multidrug ... The major vault protein (MVP) is the main constituent of the vault ribonucleoprotein particle. Although the role in multidrug ... VaultはRNAタンパク質複合体で、その発現量と多剤耐性癌細胞における治療抵抗性との相関が指摘されているが、vault自体の機能
... signal recognition particle RNA; Vault RNA RNA family of the vault ribonucleoprotein complex; SCA RNA, small Cajal body- ... Abbreviations: PIWI RNA, piwi-interacting RNA; Y-RNA, small non-coding RNA components of the Ro ribonucleoprotein particle; MT- ...
N0000006320 Vasopressins N0000170381 Vasotocin N0000169626 Vault Ribonucleoprotein Particles N0000168293 VDJ Recombinases ... U5 Small Nuclear N0000169609 Ribonucleoprotein, U7 Small Nuclear N0000169605 Ribonucleoproteins N0000169627 Ribonucleoproteins ... Ribonucleoprotein K N0000169615 Heterogeneous-Nuclear Ribonucleoprotein L N0000169618 Heterogeneous-Nuclear Ribonucleoprotein U ... Small Cytoplasmic N0000169607 Ribonucleoproteins, Small Nuclear N0000169608 Ribonucleoproteins, Small Nucleolar N0000167944 ...
... evolutionarily conserved large cytoplasmic ribonucleoprotein particles of unknown fu ... The major vault protein (MVP) is the predominant constituent of ubiquitous, ... Vaults. III. Vault ribonucleoprotein particles open into flower-like structure with octagonal symmetry ... Vaults. III. Vault ribonucleoprotein particles open into flower-like structure with octagonal symmetry ...
Ribonucleoproteins, Small Nuclear. *RNA-Induced Silencing Complex. *Telomerase. *Vault Ribonucleoprotein Particles. *RNA- ... An essential ribonucleoprotein reverse transcriptase that adds telomeric DNA to the ends of eukaryotic CHROMOSOMES. ...
Responsible for the localizing and stabilizing vault RNA (vRNA) association in the vault ribonucleoprotein particle. Binds to ... Also component of the ribonucleoprotein vaults particle, a multi-subunit structure involved in nucleo-cytoplasmic transport. ... 073206 3.76 major vault protein Mvp Rattus norvegicus Required for normal vault structure. Vaults are multi-subunit structures ... Vaults may also play a role in nucleo-cytoplasmic transport. Down-regulates INFG-mediated STAT1 signaling and subsequent ...
  • The protein structure consists of an outer shell composed of 78 copies of the ~100 kDa major vault protein (MVP). (wikipedia.org)
  • Homologs of the major vault protein has been computationally found in bacteria. (wikipedia.org)
  • When the major vault protein (MVP) is expressed in insect cells, vault particles are assembled on polyribosomes in the cytoplasm. (wikipedia.org)
  • By using molecular genetic techniques to modify the gene encoding the major vault protein, vault particles have been produced with chemically active peptides attached to their sequence. (wikipedia.org)
  • The major vault protein (MVP) is the main constituent of the vault ribonucleoprotein particle. (openaire.eu)
  • Vaults are composed of many copies of the major vault protein, which assembles to form a hollow football-shaped shell. (rcsb.org)
  • Like the major vault protein, many proteins fold to form a string of repeated compact domains. (rcsb.org)
  • W. Berger, E. Steiner, M. Grusch, L. Elbling and M. Micksche (2009) Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. (rcsb.org)
  • There are huge RNP complexes such as RNA viruses, vault complex, ribosome, spliceosome , heterogeneous ribonucleoprotein particles ( hnRNP ) and smaller ones: telomerase, replicase, RNase P, aminoacyl-tRNA synthetases etc. (mdpi.com)
  • Despite not being fully elucidated, vaults have been associated with the nuclear pore complexes and their octagonal shape appears to support this. (wikipedia.org)
  • For the Special Issue "Molecular Regulation and Mechanism of Ribonucleoprotein Complexes" of the International Journal of Molecular Sciences we accept original research manuscripts and reviews highlighting different structural and functional aspects of any ribonucleoprotein сomplex. (mdpi.com)
  • The vaults consist primarily of proteins, making it difficult to stain with conventional techniques. (wikipedia.org)
  • Ribonucleoprotein сomplexes consist of ribonucleic acid s and RNA-binding protein s. (mdpi.com)
  • Inside are two associated vault proteins, TEP1 and VPARP. (wikipedia.org)
  • The three vault proteins (MVP, VPARP, and TEP1) have each been knocked out individually and in combination (VPARP and TEP1) in mice. (wikipedia.org)
  • These modified proteins are incorporated into the inside of the vault particle without altering its basic structure. (wikipedia.org)
  • Proteins and peptides can also be packaged into vaults by attachment of a packaging domain derived from the VPARP protein. (wikipedia.org)
  • A multicomponent, ribonucleoprotein complex comprised of one of the family of ARGONAUTE PROTEINS and the "guide strand" of the one of the 20- to 30-nucleotide small RNAs. (nih.gov)
  • In the late 1990s, researchers found that vaults (especially the MVP) were over-expressed in cancer patients who were diagnosed with multidrug resistance, that is the resistance against many chemotherapy treatments. (wikipedia.org)
  • Vaults have been implicated in a broad range of cellular functions including nuclear-cytoplasmic transport, mRNA localization, drug resistance, cell signaling, nuclear pore assembly, and innate immunity. (wikipedia.org)
  • If vaults are involved in essential cellular functions, it seems likely that redundant systems exist that can ameliorate their loss. (wikipedia.org)
  • Ribonucleoprotein сomplexes (RNP) are essential in all cellular life forms: Bacteria, Archaea, Eukaryotes and even in non-cellular infectious agent s - RNA viruses. (mdpi.com)
  • An essential ribonucleoprotein reverse transcriptase that adds telomeric DNA to the ends of eukaryotic CHROMOSOMES . (nih.gov)
  • Vaults from rat liver cells. (rcsb.org)
  • In our own cells, vaults are a spectacular example of these protein-enclosed compartments. (rcsb.org)
  • Inside cells, the vault also encloses a few other molecules, which were not seen in the crystal structure because they don't have a symmetrical structure inside the vault. (rcsb.org)
  • Vaults from higher eukaryotes also contain one or several small vault RNAs (vRNAs, also known as vtRNAs) of 86-141 bases within. (wikipedia.org)
  • The vault or vault cytoplasmic ribonucleoprotein is a eukaryotic organelle whose function is not yet fully understood. (wikipedia.org)
  • From the N-terminal to the C-terminal, a MVP subunit folds into 9 repeat domains, 1 band7-like shoulder domain, 1 cap-helix domain, and 1 cap-ring domain, corresponding to the shape of the vault shell. (wikipedia.org)
  • Despite these exceptions, the high degree of similarity of vaults in organisms that do have them implies some sort of evolutionary importance. (wikipedia.org)
  • The vault is a huge symmetrical structure composed of 78 identical chains. (rcsb.org)
  • Large cytoplasmic ribonucleoprotein particles that have an eight-fold symmetry with a central pore and petal-like structure giving the appearance of an octagonal dome. (nih.gov)
  • The major vault protein (MVP) is the predominant constituent of ubiquitous, evolutionarily conserved large cytoplasmic ribonucleoprotein particles of unknown function. (silverchair.com)
  • In the late 1990s, researchers found that vaults (especially the MVP) were over-expressed in cancer patients who were diagnosed with multidrug resistance, that is the resistance against many chemotherapy treatments. (wikipedia.org)
  • 13. Expression profiles of vault components MVP, TEP1 and vPARP and their correlation to other multidrug resistance proteins in ovarian cancer. (nih.gov)
  • 16. Cellular functions of vaults and their involvement in multidrug resistance. (nih.gov)
  • Although the role in multidrug resistance has been suggested, the physiological function of vaults remains unclear. (openaire.eu)
  • 1. Cryoelectron microscopy imaging of recombinant and tissue derived vaults: localization of the MVP N termini and VPARP. (nih.gov)
  • Nonetheless, we and other folks [26?8] also found that recombinant vaults can interact with host immune cells and display self-adjuvanting properties, distinguishing them from other vaccine preparations. (dhfrinhibitor.com)
  • In addition, we reported that vaults engineered to include a recombinant Chlamydia protein (MOMP-vault vaccine) induced robust protective anti-chlamydial immune responses with no eliciting excessive inflammation as measured by TNF- production [29]. (dhfrinhibitor.com)
  • 2. The formation of vault-tubes: a dynamic interaction between vaults and vault PARP. (nih.gov)
  • Vaults have been implicated in a broad range of cellular functions including nuclear-cytoplasmic transport, mRNA localization, drug resistance, cell signaling, nuclear pore assembly, and innate immunity. (wikipedia.org)
  • Although this does not prove that increased number of vaults led to drug resistance, it does hint at some sort of involvement. (wikipedia.org)
  • 20. The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines. (nih.gov)
  • RVFV's nucleocapsid protein (N) is an RNA-binding protein that is necessary for viral transcription, replication, and the production of nascent viral particles. (mdpi.com)
  • In vitro expression of MVP in insect cell can type hollow vault-like particles identical to native vaults [25]. (dhfrinhibitor.com)
  • Discovered and isolated by Nancy Kedersha and Leonard Rome in 1986, vaults are cytoplasmic organelles which, when negative-stained and viewed under an electron microscope, resemble the arches of a cathedral's vaulted ceiling, with 39-fold (or D39d) symmetry. (wikipedia.org)
  • 10. A vault ribonucleoprotein particle exhibiting 39-fold dihedral symmetry. (nih.gov)
  • 14. Vault poly(ADP-ribose) polymerase is associated with mammalian telomerase and is dispensable for telomerase function and vault structure in vivo. (nih.gov)
  • Ribonucleoproteins, Small Nuclear" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (jefferson.edu)
  • This graph shows the total number of publications written about "Ribonucleoproteins, Small Nuclear" by people in this website by year, and whether "Ribonucleoproteins, Small Nuclear" was a major or minor topic of these publications. (jefferson.edu)
  • Below are the most recent publications written about "Ribonucleoproteins, Small Nuclear" by people in Profiles. (jefferson.edu)
  • Vaults from higher eukaryotes also contain one or several small vault RNAs (vRNAs, also known as vtRNAs) of 86-141 bases within. (wikipedia.org)
  • In parallel, to precisely measure intracellular N levels, we employed multiple reaction monitoring mass spectrometry (MRM-MS). Our results show that N binds mostly to host RNAs at early stages of infection, yielding nascent virus particles of reduced infectivity. (mdpi.com)
  • Our data additional recommended that the vault vaccine induced inflammasomes, an innate immune response that could possibly account for the self-adjuvanting home of vault-vaccines upon phagocytosis. (dhfrinhibitor.com)
  • Vaults are large ribonucleoprotein particles. (wikipedia.org)
  • The Rome lab at UCLA has collaborated with a number of groups to use the baculovirus system to produce large quantities of vaults. (wikipedia.org)
  • 8. Increased susceptibility of vault poly(ADP-ribose) polymerase-deficient mice to carcinogen-induced tumorigenesis. (nih.gov)
  • Gabanella F, Butchbach ME, Saieva L, Carissimi C, Burghes AH, Pellizzoni L. Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. (jefferson.edu)
  • The NLRP3 inflammasome may also be stimulated by huge particles which include monosodium urate (MSU) crystals, silica, nanoparticles, and also the adjuvant, alum, which can bring about lysosomal damage right after engulfment by phagocytes and also the release of lysosomal proteases such as cathepsin B [36?8]. (dhfrinhibitor.com)
  • From the N-terminal to the C-terminal, a MVP subunit folds into 9 repeat domains, 1 band7-like shoulder domain, 1 cap-helix domain, and 1 cap-ring domain, corresponding to the shape of the vault shell. (wikipedia.org)
  • 6. RNA location and modeling of a WD40 repeat domain within the vault. (nih.gov)
  • 5. Sea urchin vault structure, composition, and differential localization during development. (nih.gov)

No images available that match "vault ribonucleoprotein particles"